Belite Bio, Inc
BLTE
Kedudukan dalam Saham
#3051
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the... Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
Harga Saham
$148.24
Disegerakkan terakhir: 2026-10-19
Modal Pasaran
$5.97B
Perubahan (1 hari)
3.82%
Perubahan (1 tahun)
64.04%
Negara
US
Perdagangan Belite Bio, Inc (BLTE)
Kategori
Healthcare
Sejarah pecahan saham untuk Belite Bio, Inc (BLTE)
Saham Belite Bio, Inc (simbol: BLTE) telah mengalami sejumlah 0 pecahan saham.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham BLTE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham BLTE.
Pecahan saham terkini berlaku pada Oct 20, 2026.
Satu saham BLTE yang dibeli sebelum Oct 20, 2026 kini bersamaan dengan 0 saham BLTE.
Senarai pecahan saham
| Tahun | Pecahan | Gandaan | Gandaan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | |||
Pecahan saham untuk syarikat pesaing atau serupa
| Syarikat | Bilangan pecahan saham | Gandaan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
